| Similar Articles |
|---|
 |
Chemistry World
September 6, 2013
Dinsa Sachan |
Another drug suspension overturned in India An Indian high court has quashed the suspension of a popular antidepressant. This comes shortly after the suspension of the diabetes drug pioglitazone was overturned.   |
Chemistry World
August 5, 2014
Dinsa Sachan |
Price caps provoke lawsuits from Indian pharma industry The Indian pharma industry is engaged in a pitched battle with the drug price regulator that recently brought certain drugs under price control. |
Chemistry World
September 24, 2010
Andrew Turley |
End of the road for Avandia? The European Medicines Agency has decided the troubled diabetes drug should be pulled from the market while the US Food and Drug Administration has said it will 'significantly restrict' its use. |
Chemistry World
January 15, 2014
Dinsa Sachan |
Radical drug rule changes hit buffers in India A parliamentary panel in India has slammed a proposed bill seeking to radically alter the way drugs are regulated in India. The panel's report has essentially put reform of medicines in the country on ice, according to observers. |
Pharmaceutical Executive
October 1, 2005 |
Changing Diabetes An interview with Novo Nordisk's president of U.S. operations Martin Soeters on how a nation that leads the world in diabetes research does such a poor job of treating it. Here, he offers some solutions. |
Nursing Management
January 2012
Lawrence et al. |
Type 2 Diabetes: Growing to Epic Proportions Affecting all age groups and all aspects of a person's life, diabetes is a major public health issue worldwide, requiring lifelong behavioral and lifestyle changes and support. |
American Family Physician
May 1, 2001
Beatriz Luna & Mark N. Feinglos |
Oral Agents in the Management of Type 2 Diabetes Mellitus Currently, there are five distinct classes of hypoglycemic agents available, each class displaying unique pharmacologic properties... |
Managed Care
May 2006
Fadia T. Shaya & Deshpande |
New Treatment Approaches To Diabetes The goal of diabetes management is maintaining glycemic control while targeting quality of life improvements. |
Managed Care
May 2007
Rachel M. Renshaw |
Keys to Diabetes Control? Patience, Persistence, and Perseverance Careful attention to a comprehensive treatment plan could forestall or prevent the need to add drugs and costs to a patient's regimen. |
American Family Physician
May 1, 2001 |
Treatment Options for Type 2 Diabetes -- What's Available? What are the different steps in managing my diabetes? What are the different types of medicines used to treat type 2 diabetes and how do they work? |
The Motley Fool
July 8, 2008
Brian Lawler |
Blockbuster Drugs Bound for Extinction? One of the biggest classes of prescription drugs, those for diabetes treatments, faces tougher FDA standards. |
The Motley Fool
November 24, 2010
Brian Orelli |
Profit From the United States of Diabetes Half the country could have an early form by 2020. |
Pharmaceutical Executive
February 1, 2007
Iaquinto & Palmisano |
Medical Education: A Platform for Success By pumping the science behind a brand, pharmaceutical companies can garner early loyalist - before a drug even hits the market. |
Pharmaceutical Executive
December 1, 2006 |
Thoughtleader: Thomas Ebeling, Novartis The Next Big Thing: An interview with the pharma's CEO, who has witnessed tremendous financial and scientific growth at the company and is on the brink of his next major milestone. |
American Family Physician
August 1, 2004
Mayfield & White |
Insulin Therapy for Type 2 Diabetes: Rescue, Augmentation, and Replacement of Beta-Cell Function New insulin preparations and a better understanding of insulin physiology provide more options for family physicians attempting to effectively tailor insulin therapy to the needs of individual patients. |
The Motley Fool
June 28, 2010
Luke Timmerman |
Orexigen Drug Shows Potential as "Two-Fer" Against Obesity and Diabetes Orexigen's latest drug aims at treating both diabetes and obesity. |
Pharmaceutical Executive
April 1, 2014
Subramanian et al. |
"Market-Based" Price Controls In India? Three strategic implications for pharma pricing strategies in India. |
Managed Care
June 2007 |
Seventy Percent Surge In Diabetes Spending Spending on endocrine and diabetes therapies could surge nearly 70% in the next two years, according to research. Diabetes treatments were the second leading contributor in total dollars to prescription drug spending growth in 2006. |
AskMen.com
April 29, 2001
Joshua Levine |
Do You Have Diabetes? Diabetes is not contagious; people cannot "catch" it from one another. However, certain factors can increase one's risk of developing the disease... |
Nurse Practitioner
May 2011
Stacey A. Seggelke |
Hitting the target for inpatient glycemic management An understanding of glycemic treatment options for hospitalized patients is essential for good patient outcomes. |
Pharmaceutical Executive
March 1, 2013
Ben Comer |
Brand of the Year: Januvia When Merck's Januvia received its first regulatory approval, in Mexico in 2006, no one predicted its long-term success. In 2012, the company's diabetes franchise became the highest-selling product family in Merck's 122-year history. |
Chemistry World
May 3, 2013
Phillip Broadwith |
Judge reverses jury decision over $6.5m Takeda payout A judge has thrown out the jury's verdict in a case between Japanese drugmaker Takeda and a US man who claims that the company's drug caused his bladder cancer. |
American Family Physician
September 15, 2006
Havas & Donner |
Tight Control of Type 1 Diabetes: Recommendations for Patients Physicians play an important role in helping type 1 diabetes patients make essential lifestyle changes to help reduce the risk of microvascular and macrovascular complications. |
Pharmaceutical Executive
August 1, 2008
Gayle Lorenzi et al. |
Spanning the Treatment Gap How a diabetes field team helped docs overcome the treatment gap. |
The Motley Fool
June 30, 2011
David Williamson |
Biotech Takes On the Next Big Problem The news coming out of this week's annual conference of the American Diabetes Association wasn't good. |
Chemistry World
October 29, 2014
Phillip Broadwith |
Judge slashes fines in drug safety case A US judge has once again overturned a jury's decision to extract massive damages from pharmaceutical firms Takeda and Eli Lilly in a case concerning diabetes drug Actos (pioglitazone). |
American Family Physician
March 15, 2001
Goutham Rao |
Insulin Resistance Syndrome Insulin resistance can be linked to diabetes, hypertension, dyslipidemia, cardiovascular disease and other abnormalities. Because resistance usually develops long before these diseases appear, identifying and treating insulin-resistant patients has potentially great preventive value... |
American Family Physician
November 1, 2003
Turok et al. |
Management of Gestational Diabetes Mellitus Although the disorder affects approximately 2.5 percent of pregnant women and has been the subject of extensive research, its diagnosis and management continue to be debated. |
Food Processing
August 2013
Mark Anthony |
The Condemnation of Carbohydrates: A Food Manufacturers Guide to Understanding Diabetes The commonly held notion that sugar intake equals diabetes is a kind of unofficial dogma. But like many dogmas, this one falls apart upon closer examination. |
AskMen.com
Alex Santoso |
What You Should Know About Diabetes Not many men understand what diabetes is, why it's very bad for them (it is one of the leading causes of impotence), what they can do to avoid getting it or how to treat it. |
American Family Physician
October 15, 2000
Matthew Neff |
Conference Highlights Lifestyle Modifications Can Prevent Onset of Type 2 Diabetes... Efficacy of Metformin Is Similar in Children and Adults... Glycemic Control Improves Quality of Life in Patients with Diabetes... Test Strip Proves Effective, Less Painful Alternative to Fingerstick... |
The Motley Fool
September 30, 2011
Brian Orelli |
A Drug Market That's 366 Million Strong Diabetes drugs have potential. |
BusinessWeek
April 18, 2005
Manjeet Kripalani |
India: Bigger Pharma Tougher patent protection laws are spurring rapid growth in new drug research across India. |
The Motley Fool
October 27, 2005
Stephen D. Simpson |
What's New With Novo? Novo Nordisk is a good play on diabetes, but will new drugs reduce the need for insulin? Investors, take note. |
BusinessWeek
April 30, 2010
Drew Armstrong |
The Lobbying for Death by Diabetes How a health-reform provision may help spur sales of insulin. |
American Family Physician
October 15, 2003
Gavin et al. |
Reducing Cardiovascular Disease Risk in Patients with Type 2 Diabetes By increasing patient awareness of the link between diabetes and heart disease, family physicians can encourage patients to take medications (including aspirin), stop smoking, lower blood pressure, and lower cholesterol and blood glucose levels. |
Nursing
November 2009
Christine Kessler |
Glycemic control in the hospital: How tight should it be? Based on recent studies, the answer to that question remains controversial. This article will explore this issue and present current best practices for caring for a patient in the hospital who has diabetes or hyperglycemia. |
BusinessWeek
December 22, 2003
Arlene Weintraub |
Big Pharma Looks Beyond Insulin Researchers may be on the verge of major new treatments for diabetes and obesity. |
American Family Physician
December 15, 2000
Alan J. Garber |
Attenuating Cardiovascular Risk Factors in Patients with Type 2 Diabetes All cardiovascular risk factors except smoking are more prevalent in patients with type 2 diabetes. In addition to exercise, weight control, aspirin therapy and blood pressure control, therapy to modify lipid profiles is usually necessary... |
American Family Physician
November 1, 2000 |
Diabetes: How Do I Know if I Have it? Diabetes is a disease that occurs when your body doesn't make enough of a hormone called insulin, or if your body doesn't use insulin the right way. If left untreated, it may result in blindness, heart attacks, strokes, kidney failure and amputations... |
The Motley Fool
June 29, 2010
Brian Orelli |
Diabetes Drug Development Pops and Drops When companies present at a major meeting, there's bound to be both. |
Managed Care
July 2004
Udaya M. Kabadi |
Cost-Effective Management of Hyperglycemia in Patients with Type 2 Diabetes Using Oral Agents Sulfonylureas are cost-effective and also may be the only oral agents that inhibit processes inducing hyperglycemia by improving insulin secretion and insulin resistance. New long-acting agents hold even greater promise. |
American Family Physician
April 15, 2004
Rao, Disraeli & Mcgregor |
Impaired Glucose Tolerance and Impaired Fasting Glucose Impaired glucose tolerance and impaired fasting glucose form an intermediate stage in the natural history of diabetes mellitus. |
The Motley Fool
June 27, 2008
Brian Lawler |
This Drug Market Is Booming One therapeutic category seems to be expanding significantly faster than most of its peers, the one that helps the unfortunately burgeoning number of diabetics in the U.S. and worldwide. |
Managed Care
March 2001 |
A Comparison of Diabetes Patients' Self-Reported Health Status With Hemoglobin A1c Test Results There were substantive differences noted between diabetes patients' self-reported health status, their level of satisfaction with the care they received, and the actual care they received... |
Pharmaceutical Executive
July 3, 2007 |
Thought Leader: Connected Markets, Rob Dhoble It used to be that pharma companies had one marketing strategy for the US and other developed nations, a second strategy for emerging countries, and a third, mostly focused around access, for the developing world. But in a global environment, that doesn't work. |
American Family Physician
October 15, 2001
Anne D. Walling |
Family Practice International Diabetes in Patients from the Indian Subcontinent... Diabetic Dermopathy... Managing Minor Wounds in Children... Tibialis Posterior Tendon Insufficiency... |
Chemistry World
April 11, 2014
Andy Extance |
Missing safety risk emails draw $9bn Actos fine A US jury has fined Takeda and Eli Lilly $9 billion for causing a man's bladder cancer with their diabetes drug Actos (pioglitazone). |
Chemistry World
May 11, 2015
Phillip Broadwith |
Takeda offers $2.4bn to settle diabetes litigation Japanese drug company Takeda has put aside $2.7 billion to cover settlements of US product liability court cases relating to its diabetes drug Actos (pioglitazone). |
The Motley Fool
March 2, 2005
Bill Mann |
How Hated Is Pfizer? The FDA accepts Pfizer's application for what could be a monster drug, and the market yawns. |
